TP53 and sarcoma: For the LFS tumors, the Shh pathway was activated only in the MB-SHH/TP53-mutant but not in the prolactinoma or high-grade sarcoma, suggesting that the activation of this pathway is tissue/progenitor cell-dependent (Fig. 6A).